Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 715

Sort by

Sort Order Select

Journal Articles

How I treat anemia in heart failure

Inder Anand, Pankaj Gupta

Blood (2020) 136 (7): 790–800.

https://doi.org/10.1182/blood.2019004004

Published: 2020

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Pietro Merli, MD, Daria Pagliara, MD PhD, Mattia Algeri, MD, Federica Galaverna, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Mauro Montanari, MD, Giovanna Leone, MD, Stefania Gaspari, MD, Michele Massa, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Simone Biagini, MSc, Marco Becilli, MD, Elia Girolami, MSc, Roberto Carta, MD, Annalisa Ruggeri, MD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 799.

https://doi.org/10.1182/blood-2019-128416

Published: 2019

Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD

Blood (2019) 134 (Supplement_1): 793.

https://doi.org/10.1182/blood-2019-124364

Published: 2019

Journal Articles

Prediction of Risk for Adverse Pregnancy Outcomes in Women with Sickle Cell Disease

A. Kinga Malinowski, MD MSc, FRCSC, Kevin H. M. Kuo, MDMSc,FRCPC, George A. Tomlinson, PhD BSc, MSc, Richard Ward, MSc, MRCP, FRCPath, Nadine Shehata, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 1009.

https://doi.org/10.1182/blood-2019-130087

Published: 2019

Journal Articles

Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Echocardiography

Osama Mukarram, MD, Gian Lima, MD, Samuel Crooks, BA, Min Jung Kim, PhD, Agnes S Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4837.

https://doi.org/10.1182/blood-2019-128390

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Journal Articles

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Sagar Lonial, Joaquin Martinez-Lopez, MD PhD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD, Albert Oriol, Paula Rodriguez Otero, Luis Pineiro, Andrzej Jakubowiak, MD PhD, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, PhD, Martin Shreeve, Ming Qi, MD PhD, Philippe Moreau, MD

Blood (2019) 134 (Supplement_1): 1876.

https://doi.org/10.1182/blood-2019-123539

Published: 2019

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Marta Alonso Fernández de Gatta, MD PhD, Ana Martín García, MD PhD, Félix López Cadenas, MD, Díaz Peláez Elena, MD, Tamara Jimenez, Jesus Maria . Hernández-Rivas, MD, Victor Vallejo García, MD, Manuel Barreiro Pérez, MD, Lucia Rodríguez Estévez, MD, Juan Carlos Castro Garay, Diego Ávila, MD, Adolfo Alejandro Cabanillas Cabral, MD, Clara Sánchez Pablo, MD, María Díez-Campelo, MD PhD, Pedro Luís Sánchez Fernández, MD PhD

Blood (2019) 134 (Supplement_1): 1727.

https://doi.org/10.1182/blood-2019-127938

Published: 2019

Journal Articles

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Melissa Castiglione, BS, Christopher Mazzeo, BS, Ya-Ping Jiang, Juei-Suei Chen, Wei Yin, Richard Lin, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 7.

https://doi.org/10.1182/blood-2019-131372

Published: 2019

Journal Articles

The Role of Medical Comorbidities and Socioeconomic Factors in the Prevalence of Venous Thromboembolism Among Different Ethnic/Racial Groups in a Hospitalized Population

Iberia R Sosa, MD, Courtney Nicole Miller-Chism, MD, Jason L Salemi, PhD

Blood (2019) 134 (Supplement_1): 2160.

https://doi.org/10.1182/blood-2019-129142

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Qingyuan Wang, MD, Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 2054.

https://doi.org/10.1182/blood-2019-130572

Published: 2019

Journal Articles

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Ahmed Toure, BA, Yiyuan Wu, MS, Paul J Christos, Dr.P.H., M.S., Peter Martin, FRCPC, MD MS

Blood (2019) 134 (Supplement_1): 2205.

https://doi.org/10.1182/blood-2019-131567

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

Machine Learning Unveils Proteotypic Mimicry in Genetically Defined SCN Variants

Sebastian Hesse, MD, Christoph Klein, MD PhD, Rappsilber Juri, Prof., Yoko Mizoguchi, Monika Linder, PhD, Piotr Grabowski, PhD, Zahra Alizadeh, PhD, Zahra Pourpak, MD PhD, Nima Rezaei, MD PhD, Sorin Iurian, MD PhD, Ekrem Unal, MD, Fabian Hauck, MD PhD, Ralf Zimmer, Prof., Gergely Csaba, PhD

Blood (2019) 134 (Supplement_1): 3580.

https://doi.org/10.1182/blood-2019-131136

Published: 2019

Journal Articles

Left Ventricular Assist Device (LVAD) Implantation Transiently Increases Plasma TGF-β1 in Heart Failure Patients: Potential Impact of Lvad on Platelet Activation

Hendra Setiadi, PhD, Ahmed El-Banayosy, MD, Erin Krueger, PA-C, Karim Kouzbari, DDS, Gostynska Sandra, MS, David Vanhooser, MD, Aly El-Banayosy, MD, Douglas Horstmanshof, MD, James W Long, MD PhD, Jasimuddin Ahamed, PhD

Blood (2019) 134 (Supplement_1): 3616.

https://doi.org/10.1182/blood-2019-131820

Published: 2019

NARROW

How I treat anemia in heart failure

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Prediction of Risk for Adverse Pregnancy Outcomes in Women with Sickle Cell Disease

Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Echocardiography

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

The Role of Medical Comorbidities and Socioeconomic Factors in the Prevalence of Venous Thromboembolism Among Different Ethnic/Racial Groups in a Hospitalized Population

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Machine Learning Unveils Proteotypic Mimicry in Genetically Defined SCN Variants

Left Ventricular Assist Device (LVAD) Implantation Transiently Increases Plasma TGF-β1 in Heart Failure Patients: Potential Impact of Lvad on Platelet Activation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only